| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 1,921 | 2,103 | 2,067 | 2,083 | 2,249 | 2,336 | 2,320 | 2,674 | 2,526 | 2,374 | 2,454 | 2,847 |
| Expenses | 1,470 | 1,586 | 1,617 | 1,468 | 1,516 | 1,579 | 1,526 | 1,775 | 1,616 | 1,558 | 1,541 | 1,645 |
| EBITDA | 450 | 517 | 450 | 615 | 733 | 757 | 793 | 898 | 910 | 816 | 913 | 1,202 |
| Operating Profit % | 21 % | 21 % | 18 % | 25 % | 27 % | 27 % | 32 % | 32 % | 33 % | 29 % | 32 % | 34 % |
| Depreciation | 131 | 124 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 59 |
| Interest | 1 | 1 | 1 | 0 | 1 | 11 | 15 | 11 | 13 | 15 | 8 | 10 |
| Profit Before Tax | 238 | 402 | 517 | 548 | 660 | 643 | 669 | 773 | 824 | 746 | 1,016 | 1,133 |
| Tax | 138 | 179 | 180 | 188 | 231 | 133 | 171 | 160 | 200 | 195 | 249 | 290 |
| Net Profit | 100 | 223 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 854 |
| EPS in ₹ | 15.26 | 66.66 | 73.61 | 78.70 | 93.78 | 111.28 | 108.77 | 133.89 | 136.38 | 119.22 | 136.46 | 186.60 |
Pfizer
Pfizer
5,037.40
-84.00
(-1.64%)
Market Cap
23,044.96 Cr
PE Ratio
27.49
Volume
21,465.00
Day High - Low
5,110.80 - 4,987.80
52W High-Low
5,993.00 - 3,701.00
Q3 Quarterly Results are out. Check out the updated financials1 day ago
View
Key Fundamentals
Market Cap
23,044.96 Cr
EPS
136.46
PE Ratio
27.49
PB Ratio
6.10
Book Value
841.20
EBITDA
912.50
Dividend Yield
3.22 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
18.20
Debt to Equity
0.01
Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
5 Stocks Trading Below 5-Year Average PE Ratios
Jan 25, 2026
Jan 25, 2026IRB Infrastructure, Pfizer, Jyoti CNC, HBL Engineering, and Anant Raj are trading at P/E ratios 28-61 versus their 5-year averages of 32-84, suggesting potential undervaluation opportunities.
Pfizer Limited announces key senior management changes effective February 1, 2026, including appointment of Nilesh Pendse as Category Lead – Vaccines and organizational restructuring across business divisions.
Pfizer Limited receives significantly higher GST demand order of ₹8.79 crores from West Bengal authorities for FY2018-23, plans to appeal against the order citing it as non-maintainable.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,697.50 | #1 4,07,287.11 | 37.56 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 52.49 | |
6,168.50 | 1,63,754.29 | 66.27 | 9,712.00 | 18.67 | 2,191 | -1.02 | 48.87 | |
4,078.00 | 1,38,018.05 | 64.55 | 11,539.40 | 6.99 | 1,911 | 30.46 | 59.36 | |
1,331.50 | 1,07,554.81 | 23.69 | 28,409.50 | 7.12 | 5,291 | -57.18 | 35.86 | |
1,268.10 | 1,05,839.48 | 19.26 | 33,741.20 | 16.73 | 5,725 | -15.28 | 58.24 | |
2,199.30 | 1,00,463.76 | 23.23 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 56.93 | |
904.70 | 91,033.99 | #1 18.43 | 23,511.00 | 18.55 | 4,615 | -0.32 | 51.32 | |
2,060.50 | 85,058.49 | 47.59 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 42.02 | |
1,145.60 | 66,536.63 | 19.29 | 32,345.60 | 9.43 | 3,484 | 7.59 | 45.13 | |
5,402.50 | 64,594.99 | 29.06 | 13,458.30 | 3.70 | 2,216 | 10.98 | 36.02 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
3.37 %
Net Income Growth
39.23 %
Cash Flow Change
156.87 %
ROE
18.72 %
ROCE
14.12 %
EBITDA Margin (Avg.)
8.20 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 2,612 | 2,914 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 |
| Fixed Assets | 944 | 895 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 |
| Current Assets | 1,253 | 1,630 | 2,051 | 2,417 | 2,715 | 3,048 | 1,925 | 2,397 | 2,493 | 2,738 | 3,513 |
| Capital Work in Progress | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 |
| Investments | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,655 | 2,011 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 |
| Total Liabilities | 2,612 | 2,914 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 |
| Current Liabilities | 606 | 759 | 780 | 954 | 892 | 873 | 774 | 853 | 657 | 547 | 570 |
| Non Current Liabilities | 32 | 36 | 62 | 52 | 37 | 137 | 99 | 183 | 136 | 87 | 124 |
| Total Equity | 1,973 | 2,118 | 2,419 | 2,683 | 3,011 | 3,396 | 2,393 | 2,864 | 3,207 | 3,596 | 4,217 |
| Reserve & Surplus | 1,927 | 2,072 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 |
| Share Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 181 | -417 | -4 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 |
| Investing Activities | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 |
| Operating Activities | 114 | 346 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 |
| Financing Activities | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.82 % | 0.00 % | 3.33 % | 3.22 % | 3.54 % | 2.75 % | 2.18 % | 2.39 % | 2.60 % | 2.71 % |
| DIIs | 13.08 % | 8.98 % | 8.98 % | 8.84 % | 8.57 % | 7.91 % | 14.85 % | 14.93 % | 14.89 % | 14.89 % | 15.01 % | 15.15 % | 15.33 % | 15.84 % | 16.03 % | 16.79 % | 17.10 % | 17.23 % | 17.10 % | 17.05 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 15.03 % | 14.11 % | 14.11 % | 14.25 % | 14.19 % | 14.08 % | 13.94 % | 13.71 % | 13.70 % | 13.69 % | 13.61 % | 13.21 % | 12.90 % | 12.55 % | 12.15 % | 12.12 % | 12.34 % | 12.02 % | 12.08 % | 11.93 % |
| Others | 7.97 % | 12.98 % | 12.98 % | 12.99 % | 13.32 % | 14.08 % | 7.29 % | 7.43 % | 7.49 % | 7.50 % | 4.64 % | 7.72 % | 4.52 % | 4.46 % | 4.35 % | 4.41 % | 4.45 % | 4.43 % | 4.29 % | 4.39 % |
| No of Share Holders | 1,45,980 | 1,21,153 | 1,21,153 | 1,26,808 | 1,25,287 | 1,23,449 | 1,22,028 | 1,17,950 | 1,17,194 | 1,15,988 | 1,16,948 | 1,12,456 | 1,09,214 | 1,06,098 | 98,824 | 1,05,015 | 1,08,261 | 1,03,222 | 1,03,480 | 1,00,933 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 20 | 20 | 22.5 | 330 | 35 | 35 | 70 | 35 | 165 | 0.00 |
| Dividend Yield (%) | 0.92 | 0.6 | 0.56 | 7.29 | 0.8 | 1 | 1.67 | 0.87 | 3.28 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2021 |  Dividend | ₹ 30.00 /share | 11 Aug 2021 | 5,251.65 | 5,820.45 |
| 13 Aug 2021 | Dividend | ₹ 5.00 /share | 11 Aug 2021 | 5,251.65 | 5,820.45 |
| 19 Aug 2022 | Dividend | ₹ 35.00 /share | 18 Aug 2022 | 4,261.65 | 4,215.30 |
| 20 Feb 2022 | Dividend | ₹ 30.00 /share | 19 Sept 2022 | 4,277.45 | 4,346.40 |
| 11 Aug 2023 | Dividend | ₹ 5.00 /share | 11 Aug 2023 | 3,772.20 | 4,038.75 |
| 11 Aug 2023 | Dividend | ₹ 35.00 /share | 11 Aug 2023 | 3,772.20 | 4,038.75 |
| 21 Aug 2024 | Dividend | ₹ 35.00 /share | 21 Aug 2024 | 4,335.90 | 5,901.90 |
| 28 Aug 2024 |  Annual General Meeting | NA | 28 Aug 2024 | 5,842.95 | 5,862.80 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 5,673.00 | 5,308.70 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 4,784.65 | 4,516.55 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 4,249.90 | 4,411.35 |
| 09 Jul 2025 | Dividend | ₹ 30.00 /share | 09 Jul 2025 | 4,411.35 | 5,851.00 |
| 09 Jul 2025 | Dividend | ₹ 35.00 /share | 09 Jul 2025 | 4,411.35 | 5,851.00 |
| 21 Jul 2025 | Annual General Meeting | NA | 21 Jul 2025 | 4,411.35 | 5,319.50 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 5,052.80 | 5,087.05 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 5,207.60 | 4,996.20 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 4,599.20 | 4,590.30 |
Announcements
Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And
Nine Months Ended December 31 2025.5 days ago
5 days agoNewspaper Advertisement9 days ago
9 days agoBoard Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025.Jan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 20, 2026
Jan 20, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2026
Jan 09, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Disclosure under Regulation 30A of LODRDec 28, 2025
Dec 28, 2025Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Dec 24, 2025
Dec 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementDec 23, 2025
Dec 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 19, 2025
Dec 19, 2025Exclusive Supply And Marketing Agreement With Cipla Limited For Certain Products.Dec 19, 2025
Dec 19, 2025Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year
Ended September 30 2025Nov 12, 2025
Nov 12, 2025Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 03, 2025
Nov 03, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Aug 13, 2025Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Aug 11, 2025Launch Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 20 - Valent (PCV20)Aug 11, 2025
Aug 11, 2025Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 22, 2025
Jul 22, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 21, 2025
Jul 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 02, 2025
Jul 02, 2025Letter To Shareholders Providing The Weblink For Accessing The Annual Report.Jun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 29, 2025
Jun 29, 2025Reg. 34 (1) Annual Report.Jun 29, 2025
Jun 29, 2025Notice Of The 74Th Annual General Meeting Of The Company.Jun 29, 2025
Jun 29, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 23, 2025
May 23, 2025Appointment Of Cost And Secretarial AuditorMay 19, 2025
May 19, 2025Intimation Of Date Of Annual General MeetingMay 19, 2025
May 19, 2025Corporate Action-Board approves DividendMay 19, 2025
May 19, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
May 19, 2025Board Meeting Intimation for Board Meeting To Consider And Approve The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025.May 13, 2025
May 13, 2025Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 29, 2025
Apr 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane And Sale Of
Structures And Buildings Constructed Thereon To Zoetis Pharmaceutical Research Private Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2025
Mar 19, 2025Board Meeting Outcome for Marketing And Supply Agreement With Mylan Pharmaceuticals Private LimitedFeb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 14, 2025
Feb 14, 2025Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Feb 05, 2025Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Feb 05, 2025Receipt Of GST Order For A Tax Demand Interest And PenaltyFeb 04, 2025
Feb 04, 2025Levy Of Tax Demand And PenaltyFeb 03, 2025
Feb 03, 2025Integrated Filing (Financial)Feb 01, 2025
Feb 01, 2025Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane To Zoetis Pharmaceutical Research Private LimFeb 01, 2025
Feb 01, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 59.36
ATR(14)
Less Volatile 156.54
STOCH(9,6)
Neutral 72.31
STOCH RSI(14)
Overbought 87.84
MACD(12,26)
Bullish 67.60
ADX(14)
Weak Trend 23.05
UO(9)
Bearish 48.82
ROC(12)
Uptrend And Accelerating 9.53
WillR(14)
Neutral -27.55
About Pfizer
Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives,...more
Website
Chairperson NamePradip P Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
